Tiziana Life Sciences PLC Director/PDMR Shareholding (5937P)
October 20 2021 - 2:00AM
UK Regulatory
TIDMTILS
RNS Number : 5937P
Tiziana Life Sciences PLC
20 October 2021
PDMR Dealing
London, New York, 20 October 2021 - Tiziana Life Sciences plc
(Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a
biotechnology company focused on innovative therapeutics for
oncology, inflammation and infectious diseases, today announces
that it has been notified that Panetta Partners Limited, an entity
in which Gabriele Cerrone, the Executive Chairman has a beneficial
interest, purchased 60,000 ordinary shares of 3p each in the market
at a price of 55p per share.
The acquisition takes Mr Cerrone's interests from 34.208% to
34.238% (within the 1% incremental threshold under Note 11 to Rule
9 of the UK Takeover Code).
1. Details of PDMR / person closely associated
a) Name Gabriele Cerrone
------------------ -------------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------
a) Position Chairman
/ status
------------------ -------------------------------------------------
b) Initial Initial notification
notification
/amendment
------------------ -------------------------------------------------
3. Details of the issuer
---------------------------------------------------------------------
a) Name Tiziana Life Sciences plc
------------------ -------------------------------------------------
b) LEI 213800CED47HI8PIOB36
------------------ -------------------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------
a) Description Ordinary Shares of 3p each
of the
financial
instrument
------------------ -------------------------------------------------
b) Identification ISIN for Tiziana Life Sciences plc: GB00BKWNZY55
code of
the Financial
Instrument
------------------ -------------------------------------------------
c) Nature Market Purchase
of the
transaction
------------------ -------------------------------------------------
Price(s) 55p
d) and volume(s) 60,000
------------------ -------------------------------------------------
f) Date of 4 October 2021
the transaction
------------------ -------------------------------------------------
g) Place of XLON
the transaction
------------------ -------------------------------------------------
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed (NASDAQ:TLSA, UK LSE:
TILS) biotechnology company that focuses on the discovery and
development of novel molecules to treat human diseases in oncology,
inflammation and infectious diseases. In addition to Milciclib, the
Company will be shortly initiating Phase 2 studies with orally
administered Foralumab for Crohn's Disease and nasally administered
Foralumab for progressive multiple sclerosis. Foralumab is the only
fully human anti-CD3 monoclonal antibody ("mAb") in clinical
development in the world. This Phase 2 compound has potential
application in a wide range of autoimmune and inflammatory
diseases, such as Crohn's Disease, multiple sclerosis, type-1
diabetes ("T1D"), inflammatory bowel disease ("IBD"), psoriasis and
rheumatoid arthritis, where modulation of a T-cell response is
desirable. The Company is accelerating development of
anti-Interleukin 6 receptor ("IL6R") mAb, a fully human monoclonal
antibody for treatment of IL6-induced inflammation, especially for
treatment of COVID-19 patients.
For further enquiries:
For further enquiries:
Tiziana Life Sciences plc +44 (0)20 7495 2379
Gabriele Cerrone, Chairman, and founder
United States:
Investors:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
dave@redchip.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDGBDGLSBDGBC
(END) Dow Jones Newswires
October 20, 2021 02:00 ET (06:00 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Jul 2023 to Jul 2024